[go: up one dir, main page]

MA44656B1 - 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones et 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones en tant qu'inhibiteurs de pde1 - Google Patents

1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones et 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones en tant qu'inhibiteurs de pde1

Info

Publication number
MA44656B1
MA44656B1 MA44656A MA44656A MA44656B1 MA 44656 B1 MA44656 B1 MA 44656B1 MA 44656 A MA44656 A MA 44656A MA 44656 A MA44656 A MA 44656A MA 44656 B1 MA44656 B1 MA 44656B1
Authority
MA
Morocco
Prior art keywords
pyrazolo
dihydro
ones
pyrimidin
pyridin
Prior art date
Application number
MA44656A
Other languages
English (en)
Other versions
MA44656A (fr
Inventor
Karsten Juhl
Morten Langgård
Jan Kehler
Mikkel Jessing
Lars Rasmussen
Mauro Marigo
Paulo Vital
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA44656A publication Critical patent/MA44656A/fr
Publication of MA44656B1 publication Critical patent/MA44656B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones et des 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones de formule (i) en tant qu'inhibiteurs de pde1 et leur utilisation en tant que médicament, en particulier pour le traitement de troubles neurodégénératifs et de troubles psychiatriques.
MA44656A 2016-04-12 2017-04-07 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones et 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones en tant qu'inhibiteurs de pde1 MA44656B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201600221 2016-04-12
PCT/EP2017/058332 WO2017178350A1 (fr) 2016-04-12 2017-04-07 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones et 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones en tant qu'inhibiteurs de pde1

Publications (2)

Publication Number Publication Date
MA44656A MA44656A (fr) 2019-02-20
MA44656B1 true MA44656B1 (fr) 2020-10-28

Family

ID=58489694

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44656A MA44656B1 (fr) 2016-04-12 2017-04-07 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones et 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones en tant qu'inhibiteurs de pde1

Country Status (43)

Country Link
US (3) US20170291901A1 (fr)
EP (1) EP3442975B1 (fr)
JP (1) JP7093306B2 (fr)
KR (1) KR20180133413A (fr)
CN (1) CN109071549B (fr)
AR (1) AR108109A1 (fr)
AU (1) AU2017250431B2 (fr)
BR (1) BR112017026278A2 (fr)
CA (1) CA3020053A1 (fr)
CL (1) CL2018002881A1 (fr)
CO (1) CO2018010323A2 (fr)
CR (1) CR20180470A (fr)
CY (1) CY1123269T1 (fr)
DK (1) DK3442975T3 (fr)
DO (1) DOP2018000201A (fr)
EA (1) EA035197B1 (fr)
EC (1) ECSP18074641A (fr)
ES (1) ES2814289T3 (fr)
GE (2) GEAP201914901A (fr)
HR (1) HRP20201331T1 (fr)
HU (1) HUE050320T2 (fr)
IL (1) IL262257B (fr)
LT (1) LT3442975T (fr)
MA (1) MA44656B1 (fr)
ME (1) ME03820B (fr)
MX (1) MX374251B (fr)
MY (1) MY194722A (fr)
NI (1) NI201800092A (fr)
PE (1) PE20181853A1 (fr)
PH (1) PH12018502168A1 (fr)
PL (1) PL3442975T3 (fr)
PT (1) PT3442975T (fr)
RS (1) RS60714B1 (fr)
RU (1) RU2018133391A (fr)
SG (1) SG11201808221QA (fr)
SI (1) SI3442975T1 (fr)
SM (1) SMT202000446T1 (fr)
SV (1) SV2018005753A (fr)
TN (1) TN2018000321A1 (fr)
TW (1) TWI729109B (fr)
UA (1) UA121925C2 (fr)
WO (1) WO2017178350A1 (fr)
ZA (1) ZA201806407B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
CN109843884B (zh) 2016-10-18 2022-03-04 H.隆德贝克有限公司 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮
RS60716B1 (sr) 2016-10-28 2020-09-30 H Lundbeck As Kombinovane terapije koje obuhvataju imidazopirazinone za lečenje psihijatrijskih i/ili kognitivnih poremećaja
MX2019004859A (es) 2016-10-28 2019-06-20 H Lundbeck As Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
ES2902365T3 (es) * 2017-11-27 2022-03-28 Dart Neuroscience Llc Compuestos de furanopirimidina sustituidos como inhibidores de PDE1
AU2019275453B2 (en) 2018-05-25 2023-12-21 Intra-Cellular Therapies, Inc. Organic compounds
JP7706375B2 (ja) 2019-04-12 2025-07-11 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
CN115304607B (zh) * 2022-07-06 2023-06-27 华南农业大学 吡唑并嘧啶衍生物的制备方法

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB973361A (en) * 1960-05-11 1964-10-28 Ciba Ltd Pyrazolo-pyrimidines and process for their manufacture
DE19709877A1 (de) 1997-03-11 1998-09-17 Bayer Ag 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE10238723A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Phenyl-substituierte Pyrazolyprimidine
DE10238724A1 (de) * 2002-08-23 2004-03-04 Bayer Ag Alkyl-substituierte Pyrazolpyrimidine
JP2006525966A (ja) * 2003-05-09 2006-11-16 バイエル・ヘルスケア・アクチェンゲゼルシャフト ６−シクリルメチル−および６−アルキルメチル置換ピラゾロピリミジン類
US7872124B2 (en) 2004-12-21 2011-01-18 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
EP1919287A4 (fr) 2005-08-23 2010-04-28 Intra Cellular Therapies Inc Composés organiques pour traiter un signald'activité réduit du récepteur de la dopamine
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
EP2089034A4 (fr) 2006-12-05 2010-07-28 Intra Cellular Therapies Inc Nouvelles utilisations
GEP20125405B (en) * 2007-05-11 2012-02-27 Pfizer Amino-heterocyclic compounds
CA2706986A1 (fr) 2007-11-30 2009-06-04 Elbion Gmbh Imidazo[1,5-a]pyrazines fusionnees a aryle et heteroaryle comme inhibiteur de la phosphodiesterase 10
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
NZ590788A (en) 2008-09-08 2012-11-30 Boehringer Ingelheim Int Pyrazolopyrimidines and their use for the treatment of cns disorders
GEP20146046B (en) 2008-12-06 2014-02-25 Intracellular Therapies Inc Organic compounds
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
US9434730B2 (en) * 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
WO2012040230A1 (fr) 2010-09-20 2012-03-29 Envivo Pharmaceuticals, Inc. Composés imidazotriazinones
WO2012040048A2 (fr) 2010-09-21 2012-03-29 Schering Corporation Triazolopyrazinones comme antagonistes des récepteurs p2x7
JO3089B1 (ar) 2010-11-19 2017-03-15 H Lundbeck As مشتقات ايميدازول كمثبطات لانزيمات pde10a
WO2012136552A1 (fr) 2011-04-08 2012-10-11 H. Lundbeck A/S Anticorps spécifiquement dirigés contre la protéine bêta-amyloïde pyroglutamatée
EP2717877B1 (fr) 2011-06-10 2017-11-08 Intra-Cellular Therapies, Inc. Composés organiques
IN2015DN02829A (fr) 2011-10-10 2015-09-11 Lundbeck & Co As H
CN107082783B (zh) 2012-01-26 2019-03-22 H.隆德贝克有限公司 具有咪唑并三嗪酮骨架的pde9抑制剂
WO2013192225A1 (fr) 2012-06-18 2013-12-27 Dart Neuroscience (Cayman) Ltd Composés azolopyrimidine-5-(6h)-ones à thiophène et furane fusionnés substitués
AU2014234990B2 (en) 2013-03-15 2017-11-16 Intra-Cellular Therapies, Inc. Organic compounds
JP5783297B2 (ja) 2013-08-06 2015-09-24 株式会社デンソー 力学量センサ
TW201609713A (zh) * 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺
JP5797815B1 (ja) 2014-06-27 2015-10-21 細田建設株式会社 後施工アンカー及びその施工方法
JP2017527606A (ja) 2014-09-18 2017-09-21 サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． 三環系誘導体
US20160083391A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic piperazine derivative
US20160083400A1 (en) 2014-09-18 2016-03-24 Sunovion Pharmaceuticals Inc. Tricyclic guanidine derivative
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
TW201639851A (zh) 2015-03-16 2016-11-16 大日本住友製藥股份有限公司 雙環咪唑衍生物
TW201643167A (zh) 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI609870B (zh) 2016-02-12 2018-01-01 美國禮來大藥廠 Pde1抑制劑
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
JP2018076285A (ja) 2016-09-14 2018-05-17 大日本住友製薬株式会社 二環性イミダゾロ誘導体を含む医薬
CN109843884B (zh) 2016-10-18 2022-03-04 H.隆德贝克有限公司 作为pde1抑制剂的咪唑并吡嗪酮、吡唑并嘧啶酮和吡唑并吡啶酮
RS60716B1 (sr) 2016-10-28 2020-09-30 H Lundbeck As Kombinovane terapije koje obuhvataju imidazopirazinone za lečenje psihijatrijskih i/ili kognitivnih poremećaja
MX2019004859A (es) 2016-10-28 2019-06-20 H Lundbeck As Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.

Also Published As

Publication number Publication date
RS60714B1 (sr) 2020-09-30
EP3442975B1 (fr) 2020-07-29
US10538525B2 (en) 2020-01-21
AR108109A1 (es) 2018-07-18
EA035197B1 (ru) 2020-05-14
US11104680B2 (en) 2021-08-31
RU2018133391A (ru) 2020-05-12
IL262257B (en) 2020-11-30
UA121925C2 (uk) 2020-08-10
DOP2018000201A (es) 2018-11-15
TWI729109B (zh) 2021-06-01
MY194722A (en) 2022-12-15
TN2018000321A1 (en) 2020-01-16
US20190194204A1 (en) 2019-06-27
SV2018005753A (es) 2018-11-27
KR20180133413A (ko) 2018-12-14
WO2017178350A1 (fr) 2017-10-19
HUE050320T2 (hu) 2020-11-30
SMT202000446T1 (it) 2020-09-10
MX374251B (es) 2025-03-05
TW201738242A (zh) 2017-11-01
SG11201808221QA (en) 2018-10-30
ES2814289T3 (es) 2021-03-26
AU2017250431A1 (en) 2018-10-11
JP2019517996A (ja) 2019-06-27
SI3442975T1 (sl) 2020-10-30
AU2017250431B2 (en) 2020-07-16
EP3442975A1 (fr) 2019-02-20
ZA201806407B (en) 2019-12-18
HRP20201331T1 (hr) 2020-11-27
NI201800092A (es) 2019-03-14
GEP20207057B (en) 2020-01-27
ME03820B (fr) 2021-04-20
PL3442975T3 (pl) 2020-11-16
PH12018502168A1 (en) 2019-08-19
IL262257A (en) 2018-11-29
EA201891897A1 (ru) 2019-03-29
CA3020053A1 (fr) 2017-10-19
CY1123269T1 (el) 2021-12-31
PT3442975T (pt) 2020-09-03
LT3442975T (lt) 2020-09-25
US20170291901A1 (en) 2017-10-12
ECSP18074641A (es) 2018-10-31
CN109071549B (zh) 2021-11-30
CR20180470A (es) 2018-12-21
JP7093306B2 (ja) 2022-06-29
US20200102316A1 (en) 2020-04-02
PE20181853A1 (es) 2018-12-03
CL2018002881A1 (es) 2018-12-14
RU2018133391A3 (fr) 2020-06-23
BR112017026278A2 (pt) 2018-09-11
MA44656A (fr) 2019-02-20
CO2018010323A2 (es) 2018-12-14
GEAP201914901A (en) 2019-09-25
MX2018012496A (es) 2019-02-21
CN109071549A (zh) 2018-12-21
DK3442975T3 (da) 2020-08-24

Similar Documents

Publication Publication Date Title
MA44656A (fr) 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones et 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones en tant qu'inhibiteurs de pde1
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
MA43169B1 (fr) Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma
EA201891067A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИН-7-ИЛЬНОЕ СОЕДИНЕНИЕ
EA201990657A1 (ru) Соединения и композиции в качестве ингибиторов эндосомальных toll-подобных рецепторов
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
JOP20180116A1 (ar) H1- بيرازولو [4، 3-b] بيريدينات كمثبطات PDE1
MA42376A (fr) Dérivés d'oxopyridine substitués
EA201991109A1 (ru) ПРОИЗВОДНЫЕ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
PH12016501307B1 (en) Compounds
MA43828A (fr) Agents thérapeutiques pour maladies neurodégénératives
MA35508B1 (fr) Inhibiteurs pyrimidines de pde10
PH12015501586A1 (en) 2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
MA39170B1 (fr) Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer
MA39837B1 (fr) Quinazoline-thf-amines halogénées en tant qu'inhibiteurs de la pde1
EA201991094A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
WO2017177024A8 (fr) Méthodes de traitement de troubles oculaires
EA201990973A1 (ru) СОЕДИНЕНИЯ [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ PDE2
MA39230B1 (fr) Hexahydrofuropyrroles utilisés comme inhibiteurs de pde1
MA39027B1 (fr) Pyrido[4,3-b]pyrazine-2-carboxamides utilisées en tant qu'agents neurogènes dans le traitement des troubles neurodégénératifs
MA39533A1 (fr) Composés, composition pharmaceutique et leur utilisation dans le traitement de maladies neurodégénératives
MA45537B1 (fr) 1h-pyrazolo [4,3-b]pyridines en tant qu'inhibiteurs de pde1
MA39118A1 (fr) Quinazoline-thf-amines utilisées en tant qu'inhibiteurs de la pde1
WO2015189830A9 (fr) Composés inhibiteurs doubles utilisables dans le traitement de troubles neurodégénératifs et de la maladie d'alzheimer
MA39260A1 (fr) (benzyl-cyano-méthyl)-amides substitués de l'acide 2-aza-bicyclo[2.2.1]heptane-3-carboxylique utilisés comme inhibiteurs de la cathépsine c